{"generic":"Galsulfase","drugs":["Galsulfase","Naglazyme"],"mono":{"0":{"id":"928409-s-0","title":"Generic Names","mono":"Galsulfase"},"1":{"id":"928409-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928409-s-1-4","title":"Adult Dosing","mono":"<b>Maroteaux-Lamy syndrome:<\/b> 1 mg\/kg IV once weekly infused over a period of at least 4 hours; initial infusion rate (250 mL infusion) 6 mL\/hr for first hour; may increase rate to 80 mL\/hr for remaining 3 hours; pretreatment with antihistamines with or without antipyretics recommended 30 to 60 minutes prior to start of infusion "},"1":{"id":"928409-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>efficacy in patients younger than 5 years of age has not been evaluated<\/li><li><b>Maroteaux-Lamy syndrome:<\/b> 1 mg\/kg IV once weekly infused over a period of at least 4 hours; initial infusion rate (250 mL infusion) 6 mL\/hr for first hour; may increase rate to 80 mL\/hr for remaining 3 hours; pretreatment with antihistamines with or without antipyretics recommended 30 to 60 minutes prior to start of infusion<\/li><\/ul>"},"3":{"id":"928409-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Maroteaux-Lamy syndrome<br\/>"}}},"3":{"id":"928409-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928409-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928409-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis and severe allergic reactions, some life-threatening, have been reported during and up to 24 hours after administration; discontinue drug for severe reactions; use caution when rechallenging patients with a history of severe allergic reaction<\/li><li>apneic episodes may be exacerbated<\/li><li>febrile or respiratory illness, acute; increased risk of respiratory complications during administration; consider delaying infusion<\/li><li>fluid volume overload, susceptibility to (eg, weight of 20 kg or less, acute underlying respiratory illness, or compromised cardiac and\/or respiratory function); risk of congestive heart failure; monitoring recommended<\/li><li>infusion reactions, some serious (eg, laryngeal edema, apnea, respiratory distress, angioedema, and anaphylactoid reaction), have been reported as late as week 146 of treatment; slowing of infusion rate may be necessary; discontinue drug for severe reactions<\/li><li>spinal\/cervical cord compression (SCC) onset or worsening has been reported; may require decompression surgery; monitoring recommended<\/li><li>type 3 immune complex-mediated reactions (eg, membranous glomerulonephritis) have been reported; drug discontinuation may be warranted; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928409-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"928409-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928409-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Pruritus, Rash (21%), Urticaria<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (47%), Nausea, Vomiting<\/li><li><b>Immunologic:<\/b>Antibody development<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (42%)<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Ophthalmic:<\/b>Conjunctivitis (21%)<\/li><li><b>Otic:<\/b>Otalgia (42%)<\/li><li><b>Other:<\/b>Fever with chills, Pain (32%), Shivering (21%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis, Complication of infusion, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Spinal cord compression<\/li><li><b>Renal:<\/b>Membranous glomerulonephritis<\/li><li><b>Respiratory:<\/b>Apnea, Bronchospasm, Dyspnea (21%), Edema of larynx, Respiratory distress<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"928409-s-6","title":"Drug Name Info","sub":{"0":{"id":"928409-s-6-17","title":"US Trade Names","mono":"Naglazyme<br\/>"},"2":{"id":"928409-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Enzyme<\/li><\/ul>"},"3":{"id":"928409-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928409-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928409-s-7","title":"Mechanism Of Action","mono":"Galsulfase, a recombinant normal variant form of a polymorphic human enzyme (N-acetylgalactosamine 4-sulfase), is taken up into lysosomes, thus, increasing the catabolism of glycosaminoglycans (GAG).<br\/>"},"8":{"id":"928409-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928409-s-8-24","title":"Distribution","mono":"Vd: 69 mL\/kg (59 mL\/kg to 2,799 mL\/kg) <br\/>"},"4":{"id":"928409-s-8-27","title":"Elimination Half Life","mono":"26 min (8 min to 40 min) <br\/>"}}},"9":{"id":"928409-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV infusion only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>prepare using low-protein-binding containers; compatibility of diluted solution with glass containers is unknown<\/li><li>dilute room temperature vials with NS to final volume of 250 mL; may dilute with 100 mL for patients 20 kg and under or those who are susceptible to fluid volume overload<\/li><li>avoid agitation (agitation may denature proteins); do not use filter needle<\/li><li>infuse 250 mL infusion at 6 mL\/hr for first hour, may increase to 80 mL\/hr for remaining 3 hours as tolerated; if diluting in 100 mL adjust infusion rate so total infusion time is over at least 4 hours<\/li><li>infuse over no less than 4 hours; may extend to 20 hours if infusion reactions occur<\/li><li>administer using a low-protein-binding infusion set equipped with an in-line, low-protein-binding 0.2-micrometer filter<\/li><li>store diluted solution in refrigerator unless used immediately; administration must be completed within 48 hours of the dilution<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928409-s-10","title":"Monitoring","mono":"<ul><li>improvement in walking and stair-climbing capacity is indicative of efficacy<\/li><li>airway patency; consider evaluating prior to initiating therapy<\/li><li>acute cardiorespiratory failure; during administration, particularly in patients susceptible to fluid volume overload (eg, weight 20 kg or less, acute underlying respiratory illness, or compromised cardiac or respiratory function); prolonged observation may be required<\/li><li>immune complex-mediated reactions; during administration<\/li><li>signs and symptoms of spinal or cervical cord compression including back pain, paralysis of limbs below the level of compression, and urinary and fecal incontinence<\/li><\/ul>"},"11":{"id":"928409-s-11","title":"How Supplied","mono":"<b>Naglazyme<\/b><br\/>Intravenous Solution: 1 MG\/ML<br\/>"},"13":{"id":"928409-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause abdominal pain, nausea, vomiting, headache, rash, urticaria, pruritus, chills, pain, dyspnea, or pyrexia.<\/li><li>Drug may also cause infusion reactions including respiratory distress, laryngeal edema, chest pain, and apnea.<\/li><li>This drug may cause severe hypersensitivity reactions (including life-threatening anaphylaxis) which may appear up to 24 hours following infusion.<\/li><\/ul>"}}}